Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination
Posted On:
2020-12-29 01:49:21
(Time Zone: Arizona, USA)
Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of its novel, patent protected and globally researched Sodium Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo V and Remozen V.

Related Keywords

Arizona ,United States ,India ,Glenmark Remogliflozin ,Remogliflozin Etabonate ,Glenmark Remogliflozin Vildagiptin ,Remogliflozin Vildagliptin ,Alok Malik ,Glenmark Pharmaceuticals Limited ,Group Vice ,Sodium Glucose Co ,International Diabetes Federation ,Time Zone ,Pharmaceuticals Limited ,Sodium Glucose Co Transporter Inhibitor ,Dipeptidyl Peptidase ,Group Vice President ,Business Head ,அரிசோனா ,ஒன்றுபட்டது மாநிலங்களில் ,இந்தியா ,அலோக் மாலிக் ,க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை ,குழு துணை ,சர்வதேச நீரிழிவு நோய் கூட்டமைப்பு ,நேரம் ஸோந் ,மருந்துகள் வரையறுக்கப்பட்டவை ,குழு துணை ப்ரெஸிடெஂட் ,வணிக தலை ,